Welcome to our dedicated page for Pro-Dex Colo news (Ticker: PDEX), a resource for investors and traders seeking the latest updates and insights on Pro-Dex Colo stock.
Pro-Dex, Inc. reports developments tied to its design, development, and manufacture of powered surgical instruments, including autoclavable, battery-powered and electric multi-function surgical drivers and shavers used primarily in orthopedic, thoracic, and maxocranial facial markets. Company updates frequently address shipments of orthopedic handpieces, repair revenue, CMF drivers and batteries, engineering and regulatory services, and customer concentration around its largest medical-device customer.
Recurring news also includes quarterly operating results, contract amendments, product mix, manufacturing capacity, and corporate actions. The completed acquisition of Advanced Precision Machining LLC added a wholly owned machining subsidiary that produces machined components and sub-assemblies for medical device, aerospace, and defense-related customers.
Pro-Dex (NASDAQ:PDEX) reported strong financial results for Q4 and FY 2024. Q4 net sales increased 41% to $15.0 million, driven by a $3.4 million revenue boost from their largest customer. Q4 operating income rose 46% to $2.4 million. FY 2024 net sales grew 17% to $53.8 million, with operating income up 25% to $7.2 million. However, net income for FY 2024 decreased to $2.1 million ($0.60 per diluted share) from $7.1 million in FY 2023, primarily due to unrealized losses on marketable equity investments. The company highlighted successful growth despite transitioning to a multiple-facility operation and announced the hiring of a new Director of Operations to support future expansion.
Pro-Dex, Inc. reported strong fiscal 2024 third quarter and nine-month results with increases in net sales and operating income. However, net income declined due to unrealized losses on marketable equity investments. The company remains optimistic about future growth.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pro-Dex, Inc. (NasdaqCM:PDEX) reported its fiscal 2023 second-quarter financial results for the period ended December 31, 2022. Net sales rose by $1.1 million (11%) to $11.3 million, driven by increased sales and repair revenue from orthopedic surgical handpieces. However, gross profit decreased by $781,000 (23%) to $2.6 million due to rising component costs and higher repair expenses. Operating expenses decreased by $316,000 (18%) to $1.5 million. Net income for the quarter was $879,000 ($0.24 per diluted share), a slight drop from $925,000 ($0.25 per diluted share) in the previous year. The company anticipates growth as operations commence at its new facility.
Pro-Dex, Inc. (NASDAQ:PDEX) reported a Q1 fiscal 2023 net sales increase to $11.1 million, up 11% from $10.0 million in Q1 fiscal 2022. This growth was attributed to a $0.8 million rise in surgical handpiece repairs and a $0.7 million boost in NRE and prototype sales. However, medical device sales dipped by $397,000. The gross profit fell by 14% to $2.99 million, yielding a gross margin decrease to 27%. Net income remained stable at $1.1 million, with earnings per diluted share rising to $0.29. The FDA has authorized manufacturing at the Franklin facility, and negotiations with the largest customer are expected to yield further revenue.